Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Spark Therapeutics Inc. has 6 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 6 distinct examiners and 4 distinct art units. BRETZ, COREY LANE is the busiest examiner for the company, overseeing 1 busiest examiner pending action.
The distribution of 6 pending office actions across 6 distinct examiners indicates a decentralized prosecution strategy. With 4 distinct art units involved, the company's technical focus is spread across multiple examination groups within the Biotechnology & Pharmaceuticals sector. This 6 to 6 ratio of actions to examiners means that no single examiner has a disproportionate influence over the portfolio.
For a practitioner, managing 6 pending office actions requires coordinating with 6 distinct examiners. The involvement of 4 distinct art units suggests that while the examiners are unique, some technical overlap exists within the portfolio. BRETZ, COREY LANE handles 1 busiest examiner pending action, which matches the workload of the other distinct examiners. This level of dispersion across 4 distinct art units requires a broad understanding of different examiner tendencies.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685681 | Method of Enhancing Gene Therapy by Targeting cGAS-STING Pathway | BRETZ, COREY LANE | — |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | — |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759183 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | MATALKAH, FATIMAH KHALAF | 114d overdue |
| 18535857 | METHODS OF REGULATING ADENO-ASSOCIATED VIRUS PRODUCTION | NICOL, ALEXANDER W | — |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | — |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | — |
| 17050362 | ENGINEERED AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS COMPRISING THE ENGINEERED CAPSIDS AND METHODS OF MAKING AND USING SAME | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1634 | 1 |
| 1672 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685681 | Method of Enhancing Gene Therapy by Targeting cGAS-STING Pathway | BRETZ, COREY LANE | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18535857 | METHODS OF REGULATING ADENO-ASSOCIATED VIRUS PRODUCTION | NICOL, ALEXANDER W | 1634 | §102 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18568530 | AAV VECTOR COLUMN PURIFICATION METHODS | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 17759183 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Final Rejection | 114d overdue | Pending | Jul 20, 2022 |
| 17777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | BLUMEL, BENJAMIN P | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | May 18, 2022 |
| 17050362 | ENGINEERED AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS COMPRISING THE ENGINEERED CAPSIDS AND METHODS OF MAKING AND USING SAME | ROGERS, ERIC JASON | 1638 | §112 | Non-Final OA | — | Pending | Oct 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial